Select company
- Ticker/CompanyMarket Cap.
No results found
Select metric
Pick a metric...
$ -55.77MFree Cash Flow
VS
Market
Sector
Industry
History
$ 2.54Close
$ 1.18 - $ 11.68 52-Week Range
Ticker Information
Ticker
BTAICompany Name
BIOXCEL THERAPEUTICS INCSector
HealthcareIndustry
BiotechnologyExchange
NASDAQBIOXCEL THERAPEUTICS INC - Free Cash Flow Chart Analysis (TTM)
From
Zoom
1Y
3Y
5Y
10Y
BTAI - FCF Historical data
| Date | Capital Expenditure | Free Cash Flow | Net Cash Flow - Operations |
|---|---|---|---|
| 6/30/2025 | $ 0 | $ -55.77M | $ -55.77M |
| 3/31/2025 | $ 0 | $ -66.36M | $ -66.36M |
| 12/31/2024 | $ 0 | $ -72.03M | $ -72.03M |
| 9/30/2024 | $ 0 | $ -84.08M | $ -84.08M |
| 6/30/2024 | $ 0 | $ -105.33M | $ -105.33M |
| 3/31/2024 | $ 20K | $ -120.38M | $ -120.36M |
| 12/31/2023 | $ 20K | $ -155.03M | $ -155.01M |
| 9/30/2023 | $ 20K | $ -166.8M | $ -166.78M |
| 6/30/2023 | $ 20K | $ -160.4M | $ -160.38M |
| 3/31/2023 | $ 19K | $ -155.3M | $ -155.28M |
Key Performance Insights, Last 5 Years
- BIOXCEL THERAPEUTICS INC's latest trailing twelve months (TTM) FCF stands at $ -54.05M.
- Over the past 5 years, BIOXCEL THERAPEUTICS INC's average FCF has been $ -101.89M.
- The median FCF for BIOXCEL THERAPEUTICS INC during this period was $ -89.63M
- BIOXCEL THERAPEUTICS INC reached its highest FCF over the past 5 years at $ -54.05M.
- The lowest FCF recorded by BIOXCEL THERAPEUTICS INC in the same timeframe $ -166.8M
BIOXCEL THERAPEUTICS INC's FCF vs. competitors
We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue
FCF Benchmarks
Similar metrics to CF - Operations:
- Capital Expenditures to Operating Cash Flow - [Calculation] The CapEx to Operating Cash Flow ratio, measures how much of a company’s operating cash flow is reinvested into productive [Assets]. It is capital expenditures [CapEx] divided by net operating cash flow [NCFO].
- Capital Expenditures Coverage - [Calculation] The Capital Expenditure Ratio, or capex coverage, describes the ability of a business to generate enough cash from day-to-day operations to cover capital expenditures. It is calculated by dividing the cash flow from operations [NCFO] by its capital expenditures [CapEx].
- Free Cash Flow Yield - [Calculation] The Free Cash Flow Yield, also known as the inverse of the Price to Free Cash Flow ratio [PFCF], expresses a company’s Free Cash Flow [FCF] as a percentage of [MarketCap.
- Free Cash Flow Margin - [Calculation] A company’s Free Cash Flow [FCF] as a percentage of [Revenue]. Measures how much cash a company produces for each dollar of revenue generated.
- Free Cash Flow to Debt - [Calculation] The Free Cash Flow to Debt ratio allows investors to judge a company’s financial stability. It represents the fraction of debt that could be repaid within one year if all of the free cash flow would be used to repay debt. It is calculated by dividing Free Cash Flow [FCF] by a company’s [Liabilities].
Definition of Free Cash Flow
[Calculation] Free Cash Flow is a metric that measures the cash that remains after a company pays its operating expenses [OpEx] and capital expenditures [CapEx]. It can be calculated as Net Cash Flow from Operations [NCFO] minus capital expenditures.CF - Operations - CapEx
(=) FCF FCF for BIOXCEL THERAPEUTICS INC is calculated as follows: CF - Operations [ $ -54M ] - CapEx [ $ 48K ]
(=) FCF [ $ -54.05M ] BTAI - Free Cash Flow, Last 5 years
$ -166.8M
Minimum
Sep 30, 2023
$ -54.05M
Maximum
Sep 30, 2020
$ -101.89M
Average
$ -89.63M
Median
FCF Benchmark AnalysisMarket
The chart above depicts the distribution of FCF for companies in the Total Stock Market. The average FCF of the companies is $ 28.88M with a standard deviation of $ 118.08M.
The following table provides additional summary stats:
FCF in the Market:
| filtered constituents | 3.3K |
|---|---|
| min | $ -356.66M |
| max | $ 390M |
| average | $ 28.88M |
| median | $ 565K |
| std | $ 118.08M |